Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones

Clinical Infectious Diseases

Volumn 32, Issue SUPPL. 1, 2001, Pages

  Sanders, C C ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CROSS RESISTANCE; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MULTIPLE; QUINOLONES;

EID: 0035867014     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319369     Document Type: Review

References (54)

1. Resistance to antibacterial agent
2. Antibiotic resistance in Streptococcus pneumoniae
3. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics
4. The life and times of the Enterococcus
5. O-Acetyltransferases for chloramphenicol and other natural products
6. Aminoglycoside-aminocyclitol antibiotics and their modifying enzymes
7. β-lactamases of gram-negative bacteria: New challenges for new drugs
8. A functional classification scheme for β-lactamases and its correlation with molecular structure
9. Antibiotic resistance caused by gram-negative multidrug efflux pumps
10. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance
11. DNA gyrase, topoisomerase IV, and the 4-quinolones
12. Refining the fluoroquinolones
13. Fluoroquinolone resistance in Neisseria gonorrhoeae
14. Quinolone resistance and Campylobacter spp.
15. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa
16. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus
17. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin
18. The stability of grlA, grlB, gyrA, gyrB and norA mutations and MIC values of five fluoroquinolones in three different clonal populations of methicillin-resistant Staphylococcus aureus
19. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
20. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
21. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones
22. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa
23. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli
24. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins
25. Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium
26. Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants
27. Trends in bacterial resistance to fluoroquinolones
28. Microbiology of fluoroquinolones
29. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA
30. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus
31. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
32. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
33. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa
34. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa
35. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa over-expressing the active efflux system MexA-MexB-OprM
36. Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistance
37. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?
38. Plasmid-mediated 4-quinolone resistance: A real or apparent absence?
39. Quinolone resistance from a transferable plasmid
40. Emerging resistance to fluoroquinolones in staphylococci: An alert
41. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
42. Mechanisms of resistance to fluoroquinolones: State-of-the-art 1992-1994
43. Fluoroquinolone resistance in staphylococci: New challenges
44. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus
45. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
46. In vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis
47. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus
48. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus
49. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
50. Primary targets of fluoroquinolones in Streptococcus pneumoniae
51. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus
52. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates
53. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus
54. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus